NGNE · Neurogene Inc.
$37.34
+0.03 (+0.08%)
At close · Jul 20
Market Cap
$590.04M
Shares
15.80M
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2025
| Executive | Role | Total |
|---|---|---|
| Rachel McMinn | CEO | $3,209,553 |
| Christine Mikail | CFO | $2,754,458 |
| Julie Jordan | Chief Medical Officer | $1,472,307 |
Fiscal 2024
| Executive | Role | Total |
|---|---|---|
| Rachel McMinn | CEO | $3,464,815 |
| Christine Mikail | CFO | $3,362,174 |
| Julie Jordan | Chief Medical Officer | $2,460,036 |
Fiscal 2023
| Executive | Role | Total |
|---|---|---|
| Donna Cochener | CEO | $1,827,432 |
| Sean Smith | CFO | $1,809,783 |
| Christine Mikail | CFO | $1,132,484 |
| Rachel McMinn | CEO | $1,080,629 |
| Stuart Cobb | Chief Scientific Officer | $784,324 |
| Jonathan G. Drachman | CEO | $549,983 |
Fiscal 2022
| Executive | Role | Total |
|---|---|---|
| Donna Cochener | CEO | $993,899 |
| Jonathan G. Drachman | CEO | $902,179 |
| Rachel McMinn | CEO | $656,545 |
| Christine Mikail | CFO | $611,714 |
| Stuart Cobb | Chief Scientific Officer | $458,987 |
Fiscal 2019
| Executive | Role | Total |
|---|---|---|
| Jonathan G. Drachman | CEO | $3,823,038 |
| David J. Main | CEO | $1,963,928 |
| Kamran Alam | CFO | $1,199,997 |
Fiscal 2018
| Executive | Role | Total |
|---|---|---|
| David J. Main | CEO | $4,226,286 |
| Kamran Alam | CFO | $1,755,527 |
Fiscal 2017
| Executive | Role | Total |
|---|---|---|
| David J. Main | CEO | $3,040,314 |
| Kamran Alam | CFO | $1,430,509 |